Gianluca Mucciolo YOU? Author Swipe

Last 10y

The absence of IL17A favours cytotoxic cell function and improves antigen‐specific immunotherapies in pancreatic adenocarcinoma Open

Giorgia Tiberi, Alessandro Scagliotti, Claudia Curcio, Ermes Candiello, Paula Ariadna Diez Villegas , et al. · 2025

Background and Aims The pancreatic tumour microenvironment (TME) is a complex ecosystem where tumour cells, cancer‐associated fibroblasts and immune cells interact, often in ways that contribute to tumour growth. The role of interleukin (I…

Table S12 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S12

Table S11 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S11

Figures S1-S8 and legends from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Figures S1-S8 and legends

Table S1 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S1

Table S3 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S3

Table S10 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S10

Table S5 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S5

Data from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Pancreatic ductal adenocarcinoma (PDAC) contains an extensive stroma that modulates response to therapy, contributing to the dismal prognosis associated with this cancer. Evidence suggests that PDAC stromal composition is shaped by mutatio…

Table S6 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S6

Table S9 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S9

Table S8 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S8

Table S7 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S7

Table S4 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S4

Table S2 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S2

Table S13 from SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Table S13

The tumor immune microenvironment as a target for nano-therapies and patient-tailored treatments. Open

Luca Vannucci, Lenka Rajsiglová, Dmitry Stakheev, Pavol Lukáč, P. Tenti , et al. · 2025

Cancer is a complex illness with local to systemic expression. Cancer cells in relation with the constitutive components of the tissue from which they develop and the immune system elements, that interact with them to ablate the cancer cel…

SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer Open

Eloise G. Lloyd, Muntadher Jihad, Judhell S. Manansala, Wenlong Li, Priscilla S.W. Cheng , et al. · 2025

Pancreatic ductal adenocarcinoma (PDAC) contains an extensive stroma that modulates response to therapy, contributing to the dismal prognosis associated with this cancer. Evidence suggests that PDAC stromal composition is shaped by mutatio…

Protocol for the characterization of the pancreatic tumor microenvironment using organoid-derived mouse models and single-nuclei RNA sequencing Open

Muntadher Jihad, Gianluca Mucciolo, Wenlong Li, Akanksha Anand, Joaquín Araos Henríquez , et al. · 2024

PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer Open

Claudia Curcio, Gianluca Mucciolo, Cecilia Roux, Silvia Brugiapaglia, Alessandro Scagliotti , et al. · 2024

EGFR-activated myofibroblasts promote metastasis of pancreatic cancer Open

Gianluca Mucciolo, Joaquín Araos Henríquez, Muntadher Jihad, Sara Pinto Teles, Judhell S. Manansala , et al. · 2023

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Cancer-associated fibroblasts (CAFs) are recognized potential therapeutic targets, but poor understanding of these heterogeneous cell populations has limited the development o…

ERBB-activated myofibroblastic cancer-associated fibroblasts promote local metastasis of pancreatic cancer Open

Gianluca Mucciolo, Joaquín Araos Henríquez, Sara Pinto Teles, Judhell S. Manansala, Muntadher Jihad , et al. · 2022

SUMMARY Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Cancer-associated fibroblasts (CAFs) are recognized potential therapeutic targets, but poor understanding of these heterogeneous cell populations has limited the devel…

IL17A Depletion Affects the Metabolism of Macrophages Treated with Gemcitabine Open

Cecilia Roux, Gianluca Mucciolo, Joanna Kopecka, Francesco Novelli, Chiara Riganti , et al. · 2021

Background: Interleukin (IL)17A is a member of the IL17 cytokine family, which is released by both immune and non-immune cells such as tumor and stromal cells into the tumor microenvironment. IL17 receptors are also widely expressed in dif…

IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions Open

Gianluca Mucciolo, Claudia Curcio, Cecilia Roux, Wanda Y. Li, Michela Capello , et al. · 2021

Significance There are controversial data about the protumoral role of pancreatic cancer stroma, and dissecting multiple aspects will help to develop effective tailored therapies. Interleukin-17A (IL17A) has been reported to accelerate pan…

471 Pancreatic cancer therapy based on combination of DNA vaccination and PI3Kgamma inhibition Open

Francesco Novelli, Claudia Curcio, Cecilia Roux, Laura Conti, Roberta Curto , et al. · 2020

Background Pancreatic ductal adenocarcinoma (PDA) is the 4th leading cause of cancer mortality in developed countries, with one of the poorest prognoses among all cancers. Although 10–15% of patients are candidates for gross total surgical…

The dark side of immunotherapy: pancreatic cancer Open

Gianluca Mucciolo, Cecilia Roux, Alessandro Scagliotti, Silvia Brugiapaglia, Francesco Novelli , et al. · 2020

Since the journal Science deemed cancer immunotherapy as the "breakthrough of the year" in 2014, there has been an explosion of clinical trials involving immunotherapeutic approaches that, in the last decade - thanks also to the ren…

Fetching topic information...